jueves, 17 de septiembre de 2020

Biomarker Research | Articles

Biomarker Research | Articles

Biomarker Research

  1. Clinically relevant methods are not available that prioritize and validate potential therapeutic targets for individual tumors, from the vast amount of tumor descriptive expression data.
    Authors:Wen-Hsin Liu, Paulina Mrozek-Gorska, Anna-Katharina Wirth, Tobias Herold, Larissa Schwarzkopf, Dagmar Pich, Kerstin Völse, M. Camila Melo-Narváez, Michela Carlet, Wolfgang Hammerschmidt and Irmela Jeremias
    Citation:Biomarker Research 2020 8:46
    Content type:Research
     
    Published on: 
  2. The canonical and non-canonical nuclear factor-kappaB (NF-κB) signaling pathways have key roles in cancer, but studies have previously evaluated only the association of canonical transcription factors and ovar...
    Authors:Demetra H. Hufnagel, Andrew J. Wilson, Jamie Saxon, Timothy S. Blackwell, Jaclyn Watkins, Dineo Khabele, Marta A. Crispens, Fiona E. Yull and Alicia Beeghly-Fadiel
    Citation:Biomarker Research 2020 8:45
    Content type:Research
     
    Published on: 
  3. Over the past decades, it is recognized that loss of DNA damage repair (DDR) pathways is an early and frequent event in tumorigenesis, occurring in 40-50% of many cancer types. The basis of synthetic lethality...
    Authors:Aiai Gao and Mingzhou Guo
    Citation:Biomarker Research 2020 8:44
    Content type:Review
     
    Published on: 
  4. Aging and average life expectancy have been increasing at a rapid rate, while there is an exponential risk to suffer from brain-related frailties and neurodegenerative diseases as the population ages. Alzheime...
    Authors:Yuan-Yuan Chen, Min-Chang Wang, Yan-Ni Wang, He-He Hu, Qing-Quan Liu, Hai-Jing Liu and Ying-Yong Zhao
    Citation:Biomarker Research 2020 8:42
    Content type:Review
     
    Published on: 
  5. Long non-coding RNAs (lncRNAs) represent an important class of RNAs comprising more than 200 nucleotides, which are produced by RNA polymerase II. Although lacking an open reading framework and protein-encodin...
    Authors:Yuhang Xiao, Ta Xiao, Wei Ou, Zhining Wu, Jie Wu, Jinming Tang, Bo Tian, Yong Zhou, Min Su and Wenxiang Wang
    Citation:Biomarker Research 2020 8:41
    Content type:Review
     
    Published on: 
  6. Breast cancer, a malignant tumor originating from mammary epithelial tissue, is the most common cancer among women worldwide. Challenges facing the diagnosis and treatment of breast cancer necessitate the sear...
    Authors:Yujing Zhou and Xingdang Liu
    Citation:Biomarker Research 2020 8:39
    Content type:Review
     
    Published on: 
  7. Spliceosome mutations have become the most interesting mutations detected in human cancer in recent years. The spliceosome, a large, dynamic multimegadalton small nuclear ribonucleoprotein composed of small nu...
    Authors:Zhixia Zhou, Qi Gong, Yin Wang, Mengkun Li, Lu Wang, Hongfei Ding and Peifeng Li
    Citation:Biomarker Research 2020 8:38
    Content type:Review
     
    Published on: 
  8. Prognostic factors for the Coronavirus disease 2019 (COVID1–9) are not well established. This study aimed to summarize the available data on the association between the severity of COVID-19 and common hematolo...
    Authors:Celestin Danwang, Francky Teddy Endomba, Jan René Nkeck, Dominic Leandry Angong Wouna, Annie Robert and Jean Jacques Noubiap
    Citation:Biomarker Research 2020 8:37
    Content type:Review
     
    Published on: 
  9. Mixed phenotype acute leukemia (MPAL) is a rare leukemia and is regarded as a high-risk entity with a poor prognosis. Induction therapy of an acute lymphoblastic leukemia type or hybrid regimen and hematopoiet...
    Authors:Meng-Yun Li, Zhi-Hong Lin, Ming-Ming Hu, Li-Qing Kang, Xiao-xia Wu, Qi-wei Chen, Xin Kong, Jian Zhang, Hui-Ying Qiu and De-Pei Wu
    Citation:Biomarker Research 2020 8:36
    Content type:Case report
     
    Published on: 
  10. PD-1/PD-L1 blockade therapy is a promising cancer treatment strategy, which has revolutionized the treatment landscape of malignancies. Over the last decade, PD-1/PD-L1 blockade therapy has been trialed in a b...
    Authors:Jin-Yu Sun, Dengke Zhang, Songquan Wu, Min Xu, Xiao Zhou, Xiao-Jie Lu and Jiansong Ji
    Citation:Biomarker Research 2020 8:35
    Content type:Review
     
    Published on: 
  11. Early progression after the first-line R-CHOP treatment leads to a very dismal outcome and necessitates alternative treatment for patients with diffuse large B-cell lymphoma (DLBCL). This study aimed to develo...
    Authors:Jialin Ma, Zheng Yan, Jiuyang Zhang, Wenping Zhou, Zhihua Yao, Haiying Wang, Junfeng Chu, Shuna Yao, Shuang Zhao, Peipei Zhang, Yuanlin Xu, Qingxin Xia, Jie Ma, Bing Wei, Shujun Yang, Kangdong Liu…
    Citation:Biomarker Research 2020 8:33
    Content type:Research
     
    Published on: 
  12. The term “pharmacogenetics” is used to describe the study of variability in drug response due to heredity. It is associated with “gene – drug interactions”. Later on, the term “pharmacogenomics” has been intro...
    Authors:Nelly N. Miteva-Marcheva, Hristo Y. Ivanov, Dimitar K. Dimitrov and Vili K. Stoyanova
    Citation:Biomarker Research 2020 8:32
    Content type:Review
     
    Published on: 
  13. Acute myeloid leukemia (AML) is a malignant hematological neoplasm of myeloid progenitor cells. Mutations of FLT3 in its tyrosine kinase domain (FLT3-TKD) are found in ~ 8% of patients with AML, with D835Y as ...
    Authors:Yao Guo, Honghua Sun, Dengyang Zhang, Yuming Zhao, Mingxia Shi, Ming Yang, Shu Xing, Xueqi Fu, Ting Bin, Bo Lu, Shunjie Wu, Xiaojun Xu, Xuesong Xu, Yun Chen and Zhizhuang Joe Zhao
    Citation:Biomarker Research 2020 8:30
    Content type:Methodology
     
    Published on: 
  14. The recently updated European LeukemiaNet risk stratification guidelines combine cytogenetic abnormalities and genetic mutations to provide the means to triage patients with acute myeloid leukemia for optimal ...
    Authors:Era L. Pogosova-Agadjanyan, Anna Moseley, Megan Othus, Frederick R. Appelbaum, Thomas R. Chauncey, I-Ming L. Chen, Harry P. Erba, John E. Godwin, Isaac C. Jenkins, Min Fang, Mike Huynh, Kenneth J. Kopecky, Alan F. List, Jasmine Naru, Jerald P. Radich, Emily Stevens…
    Citation:Biomarker Research 2020 8:29
    Content type:Research
     
    Published on: 
  15. Beyond hemostasis, thrombosis and wound healing, it is becoming increasingly clear that platelets play an integral role in inflammatory response and immune regulation. Platelets recognize pathogenic microorgan...
    Authors:Yufei Chen, Haoxuan Zhong, Yikai Zhao, Xinping Luo and Wen Gao
    Citation:Biomarker Research 2020 8:28
    Content type:Review
     
    Published on: 
  16. The early detection of tumors upon initial diagnosis or during routine surveillance is important for improving survival outcomes. Here, we investigated the feasibility and clinical significance of circulating ...
    Authors:Qiong Li, Wei Zhang, Jiali Li, Jingkang Xiong, Jia Liu, Ting Chen, Qin Wen, Yunjing Zeng, Li Gao, Lei Gao, Cheng Zhang, Peiyan Kong, Xiangui Peng, Yao Liu, Xi Zhang and Jun Rao
    Citation:Biomarker Research 2020 8:27
    Content type:Research
     
    Published on: 
  17. Alterations of genes encoding subunits of the BAF/PBAF complexes are among the most frequent gene aberrations in human cancer. Such alterations have been shown to have an impact on tumor microenvironnement and...
    Authors:Kevin Courtet, Yec’han Laizet, Carlo Lucchesi, Alban Bessede and Antoine Italiano
    Citation:Biomarker Research 2020 8:26
    Content type:Letter to the Editor
     
    Published on: 
  18. N6-methyladenosine (m6A) is the most abundant form of mRNA modification in eukaryotes. It affects various aspects of RNA metabolism, including nuclear export, translation, decay and alternative splicing. In addit...
    Authors:Huafei Shen, Yifen Lan, Yanchun Zhao, Yuanfei Shi, Jie Jin and Wanzhuo Xie
    Citation:Biomarker Research 2020 8:24
    Content type:Review
     
    Published on: 
  19. Defect in DNA damage response (DDR) is a common feature of cancer cells, which regulates tumor growth and therapeutic response. Recently, the approval of immune checkpoint blockade (ICB) for tumors with defect...
    Authors:Jing Zhang, David J. H. Shih and Shiaw-Yih Lin
    Citation:Biomarker Research 2020 8:23
    Content type:Review
     
    Published on: 
  20. The KRAS mutation is the second most common genetic variant in Chinese non-small cell lung cancer (NSCLC) patients. At the 2019th World Conference of Lung Cancer, the KRAS G12C-specific inhibitor AMG510 showed pr...
    Authors:Si-Yang Liu, Hao Sun, Jia-Ying Zhou, Guang-Ling Jie, Zhi Xie, Yang Shao, Xian Zhang, Jun-Yi Ye, Chun-Xiang Chen, Xu-Chao Zhang, Qing Zhou, Jin-Ji Yang and Yi-Long Wu
    Citation:Biomarker Research 2020 8:22
    Content type:Research
     
    Published on: 
  21. Lysyl oxidase (LOX) has been described as necessary for premetastatic niche formation in epithelium-derived malignancies and its expression level therefore correlates with risk of metastatic disease and overal...
    Authors:Desiree Kunadt, Michael Kramer, Claudia Dill, Heidi Altmann, Lisa Wagenführ, Brigitte Mohr, Christian Thiede, Christoph Röllig, Johannes Schetelig, Martin Bornhäuser, Markus Schaich and Friedrich Stölzel
    Citation:Biomarker Research 2020 8:20
    Content type:Research
     
    Published on: 
  22. Chimeric antigen receptor T cells (CAR-T cells) therapy has been well recognized for treating B cell-derived malignancy. However, the efficacy of CAR-T cells against solid tumors remains dissatisfactory, parti...
    Authors:Le Qin, Ruocong Zhao, Dongmei Chen, Xinru Wei, Qiting Wu, Youguo Long, Zhiwu Jiang, Yangqiu Li, Haipeng Wu, Xuchao Zhang, Yilong Wu, Shuzhong Cui, Wei Wei, Huihui Yao, Zixia Liu, Su Cao…
    Citation:Biomarker Research 2020 8:19
    Content type:Research
     
    Published on: 
  23. Chimeric antigen receptor (CAR) T cell therapy, especially anti-CD19 CAR T cell therapy, has shown remarkable anticancer activity in patients with relapsed/refractory acute lymphoblastic leukemia, demonstratin...
    Authors:Yuru Nie, Weiqing Lu, Daiyu Chen, Huilin Tu, Zhenling Guo, Xuan Zhou, Meifang Li, Sanfang Tu and Yuhua Li
    Citation:Biomarker Research 2020 8:18
    Content type:Review
     
    Published on: 
  24. Acute myeloid leukemia (AML) is a clonal malignancy characterized by genetic heterogeneity due to recurrent gene mutations. Treatment with cytotoxic chemotherapy has been the standard of care for more than hal...
    Authors:Jifeng Yu, Peter Y. Z. Jiang, Hao Sun, Xia Zhang, Zhongxing Jiang, Yingmei Li and Yongping Song
    Citation:Biomarker Research 2020 8:17
    Content type:Review
     
    Published on: 
  25. For the detection of malignant mesothelioma additional markers are needed besides the established panel consisting of calretinin and mesothelin. The aim of this study was the identification and verification of...
    Authors:Daniel G. Weber, Swaantje Casjens, Alexander Brik, Irina Raiko, Martin Lehnert, Dirk Taeger, Jan Gleichenhagen, Jens Kollmeier, Torsten T. Bauer, Thomas Brüning and Georg Johnen
    Citation:Biomarker Research 2020 8:15
    Content type:Research
     
    Published on: 
  26. Treatment with chimeric antigen receptor (CAR)-engineered T cells directed against the B-cell maturation antigen (BCMA) promoted transient recovery from multiple myeloma (MM). However, the absence of this anti...
    Authors:Liqing Kang, Jian Zhang, Minghao Li, Nan Xu, Wei Qi, Jingwen Tan, Xiaoyan Lou, Zhou Yu, Juanjuan Sun, Zhenkun Wang, Chengcheng Fu, Xiaowen Tang, Haiping Dai, Jia Chen, Depei Wu and Lei Yu
    Citation:Biomarker Research 2020 8:14
    Content type:Research
     
    Published on: 
  27. Extramedullary relapse is an important cause of treatment failure among patients with acute lymphoblastic leukemia (ALL). This type of relapse is commonly observed in the central nervous system, while it is ra...
    Authors:Ze-Fa Liu, Li-Yun Chen, Jin Wang, Li-qing Kang, Hua Tang, Yao Zhou, Hai-Xia Zhou, Ai-Ning Sun, De-Pei Wu and Sheng-Li Xue
    Citation:Biomarker Research 2020 8:12
    Content type:Case report
     
    Published on: 
  28. The poor response to current PD-1/PD-L1 inhibitors in lung cancer patients requires development of novel immunotargets. Immunoglobulin-like transcript (ILT)4 is an immunosuppressive molecule mainly expressed i...
    Authors:Qing Li, Juan Li, Shuyun Wang, Jingnan Wang, Xiaozheng Chen, Dongmei Zhou, Yuying Fang, Aiqin Gao and Yuping Sun
    Citation:Biomarker Research 2020 8:11
    Content type:Research
     
    Published on: 
  29. Primary testicular lymphoma (PTL), often appearing as focal masses in the scrotum and epididymides, is the most frequent testicular tumor in aged men. Although MYD88 and CD79B mutations were the most common ge...
    Authors:Xinfeng Wang, Xiaoyu Xu, Wenzhi Cai, Haiyan Bao, Hongming Huang, Yifei Liu, Xi Yang, Changgeng Ruan, Depei Wu, Hongjie Shen and Suning Chen
    Citation:Biomarker Research 2020 8:10
    Content type:Letter to the Editor
     
    Published on: 
  30. High tumor mutation burden (TMB), which is associated with increased tumor immunogenicity, has been identified to predict improved response to immune checkpoint inhibitors (ICIs) therapy in non-small cell lung...
    Authors:Yongfeng Wu, Jinming Xu, Jiawei Xu, Yiqing Wang, Luming Wang, Wang Lv and Jian Hu
    Citation:Biomarker Research 2020 8:9
    Content type:Letter to the Editor
     
    Published on: 
  31. MiRNAs have been widely reported as the therapeutic target for hepatocellular carcinoma (HCC). However, mirna clusters, as the more impressive tumor regulatory factors, have received little attention. By deepl...
    Authors:Tao Rui, Siyi Xu, Shi Feng, Xueyou Zhang, Haitao Huang and Qi Ling
    Citation:Biomarker Research 2020 8:7
    Content type:Letter to the Editor
     
    Published on: 
  32. Altered expression of T cell immune inhibitory receptors may result in immunosuppression and associate with the poor prognosis of leukemia patients in which the leukemic bone marrow (BM) microenvironment may c...
    Authors:Jiaxiong Tan, Zhi Yu, Jingying Huang, Youchun Chen, Shuxin Huang, Danlin Yao, Ling Xu, Yuhong Lu, Shaohua Chen and Yangqiu Li
    Citation:Biomarker Research 2020 8:6
    Content type:Research
     
    Published on: 
  33. We used the Toponome Imaging System (TIS) to identify “patterns of marker expression”, referred to here as combinatorial molecular phenotypes (CMPs) in alveolar macrophages (AM) in response to the innate immun...
    Authors:David S. Phelps, Vernon M. Chinchilli, Judith Weisz, Debra Shearer, Xuesheng Zhang and Joanna Floros
    Citation:Biomarker Research 2020 8:5
    Content type:Research
     
    Published on: 
  34. The MER signaling pathway represents an attractive therapeutic target for human cancers. Growth arrest–specific protein 6 (GAS6)–induced MER phosphorylation is often unstable and difficult to detect without pe...
    Authors:Yaoyu Chen, Margaret Favata, Michelle Pusey, Jun Li, Yvonne Lo, Min Ye, Richard Wynn, Xiaozhao Wang, Wenqing Yao and Yingnan Chen
    Citation:Biomarker Research 2020 8:4
    Content type:Research
     
    Published on: 
  35. Gastric cancer is a deadly malignancy and is a prognostically unfavorable entity with restricted therapeutic strategies available. Prostate stem cell antigen (PSCA) is a glycosylphosphatidylinositol (GPI)-anch...
    Authors:Di Wu, Jiang Lv, Ruocong Zhao, Zhiping Wu, Diwei Zheng, Jingxuan Shi, Simiao Lin, Suna Wang, Qiting Wu, Youguo Long, Peng Li and Yao Yao
    Citation:Biomarker Research 2020 8:3
    Content type:Research
     
    Published on: 
  36. Thalidomide, lenalidomide and pomalidomide are immunomodulatory drugs (IMiDs) effective in the treatment of multiple myeloma, myelodysplastic syndrome (MDS) with deletion of chromosome 5q and other hematologic...
    Authors:Shaobing Gao, Shichao Wang and Yongping Song
    Citation:Biomarker Research 2020 8:2
    Content type:Review
     
    Published on: 
  37. Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer that develops in the pleural and outer layer of tissues surrounding the lungs. MPM is primarily caused by occupational exposure to asbestos ...
    Authors:Min-Kyu Kim, Hyun-won Kim, Mirae Jang, Sung Soo Oh, Suk-Joong Yong, Yangsik Jeong, Soon-Hee Jung and Jong-Whan Choi
    Citation:Biomarker Research 2020 8:1
    Content type:Research
     
    Published on: 
  38. Immunotherapy is currently under investigation in B3 Thymoma (TB3) and Thymic Carcinoma (TC). PD-L1 expression has been evaluated on a limited number of patients with selected antibodies. We aimed to analyze c...
    Authors:Isabelle Rouquette, Estelle Taranchon-Clermont, Julia Gilhodes, Maria-Virginia Bluthgen, Romain Perallon, Lara Chalabreysse, Anne De Muret, Veronique Hofman, Alexander Marx, Marie Parrens, Veronique Secq, Vincent Thomas de Montpreville, Françoise Galateau-Salle, Pierre Brousset, Julie Milia, Nicolas Girard…
    Citation:Biomarker Research 2019 7:28
    Content type:Research
     
    Published on: 
  39. Tamoxifen treatment has previously been reported to confer life-prolonging effects in patients with advanced pancreatic cancer, and most evidently so in women. None of these trials did however include biomarke...
    Authors:Gustav Andersson, Sebastian Lundgren, Margareta Heby, Björn Nodin, Jacob Elebro and Karin Jirström
    Citation:Biomarker Research 2019 7:26
    Content type:Research
     
    Published on: 
  40. Tumor-associated antigens (TAA) or cancer biomarkers are major targets for cancer therapies. Antibody- based agents targeting the cancer biomarkers include monoclonal antibodies (MoAbs), radiolabeled MoAbs, bi...
    Authors:Delong Liu
    Citation:Biomarker Research 2019 7:25
    Content type:Editorial
     
    Published on: 

No hay comentarios:

Publicar un comentario